Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01392235 | Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) | PHASE2 | COMPLETED | 58 | — | — | Jul 1, 2011 | Aug 1, 2016 | Jan 22, 2019 | 1 | China |
To evaluate the efficacy (clinical benefit rate) of single-agent famitinib in patients with recurrent or metastatic NPC
| Arm | Type | Description |
|---|---|---|
| Drug: Famitinib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Famitinib | DRUG | 25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent |
Inclusion Criteria: * Histologically or cytologic confirmed recurrent and/or metastatic nasopharyngeal carcinoma( NPC ) * Have failed for ≥2 lines of chemotherapy * At least one measurable lesion, larger than 10 mm in diameter by spiral CT scan(scanning layer ≤ 5 mm ) * ≥ 18 and ≤ 70 years of age *...